Skip to main content

Scientists Discover Way to Send Information into Black Holes Without Using Energy

Post a Comment

Scientists Create Smart Antibody-RNA Therapy That Shrinks Hard-to-Treat Tumors

In a major scientific leap, researchers have developed a new type of antibody that can accurately deliver RNA-based treatments directly into some of the most difficult-to-treat tumors. This specially engineered antibody—called TMAB3—has shown extraordinary results in preclinical studies. It not only shrank tumors but also significantly extended survival in animals with pancreatic, brain, and skin cancers.

The study, published in Science Translational Medicine, was led by a team at Yale School of Medicine and the University of Illinois Urbana-Champaign. The therapy marks a powerful advancement in cancer treatment by overcoming one of the biggest hurdles in RNA-based medicine: targeted delivery to solid tumors.

The Challenge: Delivering RNA to the Right Place

RNA therapies are one of the most promising new tools in medicine. They can activate the immune system, shut down cancer genes, and even reverse resistance to treatment. However, one key problem has held them back: how to get them inside tumors without damaging healthy cells.

According to Dr. Peter Glazer, senior author of the study and professor at Yale, “Delivery of RNA-based therapies to tumors has been a challenge. Our finding that TMAB3 can form antibody/RNA complexes capable of delivering RNA payloads to tumors provides a new approach to overcome this challenge.”

In simple terms, TMAB3 acts like a guided missile. It finds the tumor, binds to it, and injects the RNA therapy directly inside—avoiding damage to the rest of the body.

What is TMAB3 and How Does It Work?

TMAB3 is a specially engineered antibody. Antibodies are proteins used by the immune system to find and attack threats like bacteria and viruses. In this case, scientists modified an antibody so it can carry RNA, penetrate cancer cells, and release the treatment directly inside.

But TMAB3 is more than just a delivery tool. It’s also been “humanized,” meaning it has been modified to appear natural to the human immune system. This reduces the chances of being rejected by the body—an important step toward testing the therapy in humans.

To develop TMAB3, researchers used computer modeling and biotechnology to design an antibody with two special powers:

  1. It binds strongly to RNA, allowing it to carry the treatment safely through the bloodstream.

  2. It can penetrate deep into solid tumors, even in tough locations like the brain.

Once TMAB3 reaches the tumor, it releases the RNA. The RNA then activates the body's immune response, especially boosting CD8+ T cells—immune warriors that destroy cancer.

Targeting the Toughest Cancers

The scientists focused on three types of “cold” tumors. These cancers are typically unresponsive to standard treatments, including chemotherapy and immunotherapy. They include:

  • Pancreatic cancer

  • Medulloblastoma (a form of brain cancer)

  • Melanoma (skin cancer)

In animal models for all three types, TMAB3 therapy showed powerful effects.

1. Pancreatic Cancer: A Notorious Killer

Pancreatic ductal adenocarcinoma is one of the deadliest forms of cancer. It’s known for being aggressive, hard to detect early, and difficult to treat.

But with TMAB3-based therapy, tumor sizes shrank significantly. Even more importantly, animals lived longer. This was made possible by the strong immune activation—CD8+ T cells were found in larger numbers, meaning the body was fighting the cancer better.

2. Medulloblastoma: Crossing the Blood-Brain Barrier

The brain is protected by a defense system called the blood-brain barrier, which blocks most medicines. But TMAB3 succeeded in crossing this barrier and delivering RNA directly to the tumor.

The result? The brain tumors shrank, and survival times increased. Even better, there were no harmful immune responses or side effects in healthy brain tissue.

3. Melanoma: Minimal Side Effects

In models of melanoma, researchers noted dramatic tumor suppression. Animals showed minimal to no signs of toxic side effects—a common concern in cancer treatment. This suggests the therapy is not only effective but also safe.

How Was the Antibody Created? A Smart Design

Creating TMAB3 involved a blend of computer modeling and laboratory testing. Researchers first identified the right structure for the antibody so that it could “grab” the RNA molecule tightly. They then modified the antibody so it could safely travel through the bloodstream and not be rejected by the immune system.

This “humanization” is crucial for future clinical use in patients. Without it, the human body might see the antibody as an invader and attack it, rendering the treatment useless.

This smart design approach could pave the way for more antibody-RNA combinations in the future, each customized for different types of cancer.

Why Is This Discovery So Important?

This discovery is a potential game-changer in cancer treatment for several reasons:

  1. It offers a new method to deliver RNA therapies directly into tumors.

  2. It can reach cancers previously considered untreatable or “cold” to immunotherapy.

  3. It reduces harm to healthy tissues, minimizing side effects.

  4. It opens the door for personalized treatments based on a patient's specific tumor type.

As Dr. Luisa Escobar-Hoyos, co-senior author of the study, explains, “By achieving targeted delivery to tumor cells without systemic toxicity, we open the possibility of developing treatments that are not only tumor-specific but also adaptable to the immunologic context of each patient's cancer.”

What’s Next? Moving Toward Human Trials

This therapy is still in the experimental stage. So far, it’s only been tested in animal models. However, the next steps are clear:

  1. Refining the therapy for human biology

  2. Conducting safety trials in human volunteers

  3. Eventually launching clinical trials in cancer patients

If successful, this antibody-RNA platform could be adapted to treat a wide range of cancers—even those that don’t respond to existing treatments.

The researchers are optimistic. “This work lays the foundation for translating RNA-based therapies into the clinic,” said Dr. Glazer. “With further development, this platform could support personalized immuno-RNA therapies and move toward first-in-human clinical trials.”

A Collaborative Effort by Top Scientists

The study included 30 researchers from multiple departments at Yale, including:

  • Therapeutic Radiology

  • Genetics

  • Molecular Biophysics and Biochemistry

  • Pathology

  • Biomedical Engineering

  • Medical Oncology

Three additional contributors came from the University of Illinois Urbana-Champaign. This level of collaboration across disciplines shows how complex—and promising—this new technology is.

The Future of Cancer Treatment: Precision, Safety, and Hope

This breakthrough signals a shift in how we might fight cancer in the future. Instead of toxic drugs that harm both healthy and cancerous cells, we may soon use smart therapies that know exactly where to go and what to attack.

By combining antibody targeting with the power of RNA, TMAB3 represents a powerful new class of precision medicine. It’s more than a treatment—it’s a potential revolution in how we treat cancer.

As research continues, millions of people suffering from treatment-resistant cancers may soon have renewed hope.

Key Takeaways:

  • What was discovered? A new antibody called TMAB3 that can deliver RNA therapy directly into tumors.

  • Why is it important? It overcomes the major challenge of RNA therapy delivery and targets resistant cancers.

  • Which cancers were tested? Pancreatic cancer, brain cancer (medulloblastoma), and melanoma.

  • How effective was it? Tumors shrank, survival increased, and side effects were minimal in animals.

  • What’s next? Preparing for human clinical trials and potential personalized cancer treatments.

Reference:
Elias Quijano et al., Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer, Science Translational Medicine (2025). DOI: 10.1126/scitranslmed.adk1868

Comments

Post a Comment

Popular

Scientists Discover Way to Send Information into Black Holes Without Using Energy

For years, scientists believed that adding even one qubit (a unit of quantum information) to a black hole needed energy. This was based on the idea that a black hole’s entropy must increase with more information, which means it must gain energy. But a new study by Jonah Kudler-Flam and Geoff Penington changes that thinking. They found that quantum information can be teleported into a black hole without adding energy or increasing entropy . This works through a process called black hole decoherence , where “soft” radiation — very low-energy signals — carry information into the black hole. In their method, the qubit enters the black hole while a new pair of entangled particles (like Hawking radiation) is created. This keeps the total information balanced, so there's no violation of the laws of physics. The energy cost only shows up when information is erased from the outside — these are called zerobits . According to Landauer’s principle, erasing information always needs energy. But ...
Post a Comment
Read more

How Planetary Movements Might Explain Sunspot Cycles and Solar Phenomena

Sunspots, dark patches on the Sun's surface, follow a cycle of increasing and decreasing activity every 11 years. For years, scientists have relied on the dynamo model to explain this cycle. According to this model, the Sun's magnetic field is generated by the movement of plasma and the Sun's rotation. However, this model does not fully explain why the sunspot cycle is sometimes unpredictable. Lauri Jetsu, a researcher, has proposed a new approach. Jetsu’s analysis, using a method called the Discrete Chi-square Method (DCM), suggests that planetary movements, especially those of Earth, Jupiter, and Mercury, play a key role in driving the sunspot cycle. His theory focuses on Flux Transfer Events (FTEs), where the magnetic fields of these planets interact with the Sun’s magnetic field. These interactions could create the sunspots and explain other solar phenomena like the Sun’s magnetic polarity reversing every 11 years. The Sun, our closest star, has been a subject of scient...
Post a Comment
Read more

Black Holes That Never Dies

Black holes are powerful objects in space with gravity so strong that nothing can escape them. In the 1970s, Stephen Hawking showed that black holes can slowly lose energy by giving off tiny particles. This process is called Hawking radiation . Over time, the black hole gets smaller and hotter, and in the end, it disappears completely. But new research by Menezes and his team shows something different. Using a theory called Loop Quantum Gravity (LQG) , they studied black holes with quantum corrections. In their model, the black hole does not vanish completely. Instead, it stops shrinking when it reaches a very small size. This leftover is called a black hole remnant . They also studied something called grey-body factors , which affect how much energy escapes from a black hole. Their findings show that the black hole cools down and stops losing mass once it reaches a minimum mass . This new model removes the idea of a “singularity” at the center of the black hole and gives us a better ...
Post a Comment
Read more